Cancer immunotherapy via immune-checkpoint inhibition (ICI) by antibodies against cytotoxic Tlymphocyte-associated protein 4 (CTLA-4) and cell death protein 1 (PD-1) have significantly improved the outcome of metastasized melanoma and of a rapidly increasing number of other cancer types. | Challenges in diagnosis and management of neutropenia upon exposure to immunecheckpoint inhibitors Meta-analysis of a rare immune-related adverse side effect